期刊
FRONTIERS IN CHEMISTRY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2021.671483
关键词
G-protein coupled receptor; pepducin; peptidomimetic; biased signaling; allosteric modulators; drug discovery; nanobodies; peptide
资金
- NIDA [R37 DA39997]
- NIGMS [T32 GM007767]
- NIH [GM117425]
Allosteric modulators (AMs) of G-protein coupled receptors (GPCRs) present desirable drug targets due to their potential to produce fewer on-target side effects and improved selectivity compared to orthosteric drugs. Peptides and proteins, deriving from endogenous protein-protein interactions, intramolecular receptor contacts, endogenous peptides, and exogenous libraries, serve as underappreciated sources for identifying AM leads, offering advantages such as high affinity and bioactivity along with disadvantages like poor metabolic stability. Peptidomimetics combine the advantages of both peptides and small molecules, mimicking peptide chemical features responsible for bioactivity while enhancing druggability.
Allosteric modulators (AMs) of G-protein coupled receptors (GPCRs) are desirable drug targets because they can produce fewer on-target side effects, improved selectivity, and better biological specificity (e.g., biased signaling or probe dependence) than orthosteric drugs. An underappreciated source for identifying AM leads are peptides and proteins-many of which were evolutionarily selected as AMs-derived from endogenous protein-protein interactions (e.g., transducer/accessory proteins), intramolecular receptor contacts (e.g., pepducins or extracellular domains), endogenous peptides, and exogenous libraries (e.g., nanobodies or conotoxins). Peptides offer distinct advantages over small molecules, including high affinity, good tolerability, and good bioactivity, and specific disadvantages, including relatively poor metabolic stability and bioavailability. Peptidomimetics are molecules that combine the advantages of both peptides and small molecules by mimicking the peptide's chemical features responsible for bioactivity while improving its druggability. This review 1) discusses sources and strategies to identify peptide/peptidomimetic AMs, 2) overviews strategies to convert a peptide lead into more drug-like peptidomimetic, and 3) critically analyzes the advantages, disadvantages, and future directions of peptidomimetic AMs. While small molecules will and should play a vital role in AM drug discovery, peptidomimetics can complement and even exceed the advantages of small molecules, depending on the target, site, lead, and associated factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据